Advertisement Covidien To Sell Specialty Chemicals Business To New Mountain Capital - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Covidien To Sell Specialty Chemicals Business To New Mountain Capital

Covidien, a provider of healthcare products, has signed a definitive agreement to sell its specialty chemicals business to an affiliate of New Mountain Capital, for a cash purchase price of $280m.

Headquartered in Phillipsburg, New Jersey, Covidien’s specialty chemicals business, manufactures and markets high-purity chemicals and related products and services under two brand names, JT Baker and Mallinckrodt Laboratory Chemicals.

The products are widely used in research and quality control laboratories, microelectronics, environmental testing laboratories and universities, and for manufacturing in the pharmaceutical, biotechnology and other industrial markets.

Covidien said that the decision to divest specialty chemicals was made following a thorough evaluation of a number of strategic alternatives. The decision is consistent with company’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the company has or can develop a global competitive advantage.

According to Covidien, fiscal 2009 sales of the specialty chemicals product line were $414m. For the first six months of fiscal 2010, sales of the product line were $216m. Covidien is expected to report the specialty chemicals product line as a discontinued operation.

Completion of the transaction is subject to customary closing conditions, with closing expected by the end of fiscal 2010.